{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:26Z","timestamp":1793242286707,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA203721"],"award-info":[{"award-number":["R01 CA203721"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA203721"],"award-info":[{"award-number":["R01 CA203721"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"David Lamb Fund for Cutaneous T-Cell Lymphoma Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01237-5","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T18:02:26Z","timestamp":1744912946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Cecilia","family":"Larocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Tram N.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Tawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Teague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-4314","authenticated-orcid":false,"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-8584","authenticated-orcid":false,"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-834X","authenticated-orcid":false,"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"1237_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314.","journal-title":"Blood"},{"key":"1237_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.hoc.2019.04.004","volume":"33","author":"CA Larocca","year":"2019","unstructured":"Larocca CA, LeBoeuf NR. Overview of Cutaneous T-Cell Lymphomas. Hematol Oncol Clin North Am. 2019;33:669\u201386.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1237_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hon.2584","volume":"37","author":"W Kempf","year":"2019","unstructured":"Kempf W, Zimmermann AK, Mitteldorf C. Cutaneous lymphomas-An update 2019. Hematol Oncol. 2019;37:43\u20137.","journal-title":"Hematol Oncol"},{"key":"1237_CR4","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1056\/NEJMra032810","volume":"350","author":"M Girardi","year":"2004","unstructured":"Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N. Engl J Med. 2004;350:1978\u201388.","journal-title":"N. Engl J Med"},{"key":"1237_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.hoc.2018.09.001","volume":"33","author":"C Larocca","year":"2019","unstructured":"Larocca C, Kupper T. Mycosis Fungoides and Sezary Syndrome. Update Hematol Oncol Clin North Am 2019;33:103\u201320.","journal-title":"Update Hematol Oncol Clin North Am"},{"key":"1237_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","volume":"150","author":"R Watanabe","year":"2014","unstructured":"Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014;150:776\u20139.","journal-title":"JAMA Dermatol"},{"key":"1237_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767\u201371.","journal-title":"Blood"},{"key":"1237_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-59745-323-3_11","volume":"378","author":"HE Chan","year":"2007","unstructured":"Chan HE, Jilani I, Chang R, Albitar M. Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab. Methods Mol Biol. 2007;378:159\u201365.","journal-title":"Methods Mol Biol"},{"key":"1237_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cncr.11551","volume":"98","author":"A Ferrajoli","year":"2003","unstructured":"Ferrajoli A, O\u2019Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773\u20138.","journal-title":"Cancer"},{"key":"1237_CR10","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829\u201339.","journal-title":"Lancet"},{"key":"1237_CR11","doi-asserted-by":"publisher","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","volume":"4","author":"RA Clark","year":"2012","unstructured":"Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4:117ra7.","journal-title":"Sci Transl Med"},{"key":"1237_CR12","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","volume":"50","author":"C Querfeld","year":"2009","unstructured":"Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009;50:1969\u201376.","journal-title":"Leuk Lymphoma"},{"key":"1237_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","volume":"92","author":"MG Bernengo","year":"2007","unstructured":"Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, et al. Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92:784\u201394.","journal-title":"Haematologica"},{"key":"1237_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1086\/504811","volume":"43","author":"SI Martin","year":"2006","unstructured":"Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16\u201324.","journal-title":"Clin Infect Dis"},{"key":"1237_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1684\/ejd.2018.3444","volume":"28","author":"JR Stewart","year":"2018","unstructured":"Stewart JR, Desai N, Rizvi S, Zhu H, Goff HW. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory S\u00e9zary syndrome: a systematic review. Eur J Dermatol. 2018;28:764\u201374.","journal-title":"Eur J Dermatol"},{"key":"1237_CR16","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598\u2013607.","journal-title":"J Clin Oncol"},{"key":"1237_CR17","doi-asserted-by":"crossref","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","DOI":"10.1214\/aos\/1176350951"},{"key":"1237_CR18","first-page":"96","volume":"446","author":"J Fine","year":"1999","unstructured":"Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;446:96\u2013509.","journal-title":"J Am Stat Assoc."},{"key":"1237_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40257-016-0177-5","volume":"17","author":"S Devata","year":"2016","unstructured":"Devata S, Wilcox RA. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Am J Clin Dermatol. 2016;17:225\u201337.","journal-title":"Am J Clin Dermatol"},{"key":"1237_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0678-x","volume":"20","author":"L Photiou","year":"2018","unstructured":"Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sezary Syndrome. Curr Oncol Rep. 2018;20:32.","journal-title":"Curr Oncol Rep"},{"key":"1237_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3109\/10428191003777963","volume":"51","author":"WM Siders","year":"2010","unstructured":"Siders WM, Shields J, Garron C, Hu Y, Boutin P, Shankara S, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma. 2010;51:1293\u2013304.","journal-title":"Leuk Lymphoma"},{"key":"1237_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","volume":"128","author":"Y Hu","year":"2009","unstructured":"Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260\u201370.","journal-title":"Immunology"},{"key":"1237_CR23","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015;33:3766\u201373.","journal-title":"J Clin Oncol"},{"key":"1237_CR24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.V97.3.624","volume":"97","author":"JJ Scarisbrick","year":"2001","unstructured":"Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97:624\u201330.","journal-title":"Blood"},{"key":"1237_CR25","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-19-2742","volume":"25","author":"C Larocca","year":"2019","unstructured":"Larocca C, Kupper TS, LeBoeuf NR. Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem. Clin Cancer Res. 2019;25:7272\u20134.","journal-title":"Clin Cancer Res"},{"key":"1237_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","volume":"149","author":"SJ Whittaker","year":"2003","unstructured":"Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Dermatologists BAo, Group UKCL. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2003;149:1095\u2013107.","journal-title":"Br J Dermatol"},{"key":"1237_CR27","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/bjd.12909","volume":"170","author":"JJ Scarisbrick","year":"2014","unstructured":"Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol. 2014;170:1226\u201336.","journal-title":"Br J Dermatol"},{"key":"1237_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jid.2019.07.712","volume":"140","author":"A Mourad","year":"2020","unstructured":"Mourad A, Gniadecki R. Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2020;140:495\u20137.e5.","journal-title":"J Invest Dermatol"},{"key":"1237_CR29","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/bjd.17073","volume":"179","author":"R Blaizot","year":"2018","unstructured":"Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides\/Sezary syndrome: a retrospective cohort study. Br J Dermatol. 2018;179:1322\u20138.","journal-title":"Br J Dermatol"},{"key":"1237_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/DAD.0000000000001264","volume":"40","author":"SP Gottesman","year":"2018","unstructured":"Gottesman SP, Rosen JR, Geller JD, Freeman BB. Atypical Varicella-Zoster Kaposi Varicelliform Eruption in Sezary Syndrome. Am J Dermatopathol. 2018;40:920\u20133.","journal-title":"Am J Dermatopathol"},{"key":"1237_CR31","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.4049\/jimmunol.176.7.4431","volume":"176","author":"RA Clark","year":"2006","unstructured":"Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006;176:4431\u20139.","journal-title":"J Immunol"},{"key":"1237_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni.1718","volume":"10","author":"T Gebhardt","year":"2009","unstructured":"Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10:524\u201330.","journal-title":"Nat Immunol"},{"key":"1237_CR33","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1177\/1352458518796675","volume":"25","author":"S Wray","year":"2019","unstructured":"Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019;25:1605\u201317.","journal-title":"Mult Scler"},{"key":"1237_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2018.02.011","volume":"36","author":"L Serrano","year":"2018","unstructured":"Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in Cutaneous T-Cell Lymphoma and Its Management. Dermatol Clin. 2018;36:245\u201358.","journal-title":"Dermatol Clin"},{"key":"1237_CR35","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood. 2003;101:4267\u201372.","journal-title":"Blood"},{"key":"1237_CR36","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730\u20139.","journal-title":"J Clin Oncol."},{"key":"1237_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","volume":"9","author":"R Ottevanger","year":"2022","unstructured":"Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57\u201364.","journal-title":"JAAD Int."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01237-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01237-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01237-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T18:02:28Z","timestamp":1744912948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01237-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01237-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NRL is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics outside the submitted work. TSK is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR065807 and T32 AR007098) and the National Institute of Allergy and Infectious Diseases (grant number R01 AI127654); he is a scientific advisor for Pellis Therapeutics. CL is supported by the National Cancer Institute (grant number R37 CA252312). She has served on a medical advisory board for Kyowa Kirin. JOM is an employee of Sanofi and may hold stock and\/or stock options in the company. RC, DF, and EJ have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Approval was obtained from institutional review board (DFCI protocol #02-016) and informed patient consent was obtained from all participants for study, including for translational research investigations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"69"}}